Cytocom, Inc.
CBLI · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $0 | $1 | $1 |
| SG&A Expenses | $1 | $0 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | -295,476,949,289,196.9% | -1,771.3% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | -264,202,751,937,689.7% | -1,707.8% |
| EPS | -0.043 | -0.038 | -0.053 | -0.057 |
| % Growth | -12.7% | 29.2% | 6.8% | – |
| EPS Diluted | -0.043 | -0.038 | -0.053 | -0.057 |
| Weighted Avg Shares Out | 15 | 14 | 13 | 13 |
| Weighted Avg Shares Out Dil | 15 | 14 | 13 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | -263,193,403,868,533.7% | -1,723.6% |